Welcome to our dedicated page for ICON PLC news (Ticker: ICLR), a resource for investors and traders seeking the latest updates and insights on ICON PLC stock.
ICON plc (NASDAQ: ICLR) is a clinical research organisation headquartered in Dublin, Ireland, operating in the research and development in biotechnology industry. This news page focuses on company announcements and updates that relate to its clinical research activities, financial performance and corporate developments.
ICON’s news releases commonly cover quarterly financial results, including revenue, net income, adjusted EBITDA and related non‑GAAP measures. These updates often discuss business wins, book‑to‑bill ratios, cash generation and capital allocation decisions such as share repurchase activity, as reflected in the company’s second and third quarter 2025 results announcements.
Investors and industry observers can also find news about ICON’s participation in investor and healthcare conferences. The company regularly announces presentations at events such as global healthcare conferences and growth stock conferences, as well as the scheduling of earnings conference calls and webcasts. These items provide insight into how ICON communicates its strategy and performance to the market.
Corporate governance and leadership changes are another key news category. For example, ICON has announced a CEO transition, detailing succession planning and board decisions. The company also publishes the results of its annual general meeting, including shareholder votes on director elections, auditor ratification and share authorisations.
In addition, ICON highlights recognition of its clinical research capabilities, such as independent benchmarking reports that assess its performance in phase 1 clinical trials. News may also include updates on specific research programmes, such as vaccine study updates noted in its filings. For ongoing visibility into ICON plc’s operations, financial reporting and role as a clinical research organisation, this news feed aggregates company-issued information in one place.
Summary not available.
ICON plc (NASDAQ:ICLR) has released its 2020 Environmental, Social and Governance (ESG) Report, following its acquisition of PRA Health Sciences. The report outlines ESG advancements made by both organizations and details commitments and policies for the unified company. CEO Steve Cutler emphasized the focus on enhancing ESG strategies to make a positive impact. The complete report is accessible for review on ICON's official website.
ICON plc (NASDAQ: ICLR) announced the expansion of its Accellacare Site Network with new partnerships, enhancing its reach in four countries: the U.S., Germany, Spain, and Poland. This growth brings the total active locations to 112 across eight countries, including new sites in Florida and California. The expansion aims to increase patient access and improve clinical trial recruiting, accessing over 9 million patients. This move supports quicker drug development timelines and costs for clients, particularly in central nervous system and immune-inflammation therapeutic areas.
ICON plc (NASDAQ: ICLR) has announced participation in two upcoming conferences. CFO Brendan Brennan will present at the 30th Annual Credit Suisse Healthcare Conference on November 9, 2021, at 8:50 AM ET, and at the 4th Annual Evercore ISI HealthCONx Conference on December 1, 2021, at 12:10 PM ET. Investors can find updates and links to live webcasts on the company's Investor Relations website. With approximately 37,960 employees across 159 locations worldwide, ICON focuses on advancing clinical research and improving patient lives.
ICON plc (NASDAQ: ICLR) reported impressive Q3 2021 results with record net business wins of $2,374 million and a net book to bill ratio of 1.27. Adjusted revenue reached $1,870.4 million, marking a 167% year-on-year increase. Adjusted net income was $209.8 million, or $2.55 per diluted share. However, GAAP net loss reached $94.3 million. The company revised its full-year revenue guidance to $5,430 - $5,530 million, a 94% - 98% increase year-on-year.
ICON plc has received a €4 million funding grant from Enterprise Ireland, aimed at enhancing its digital health technology and data analytics solutions. This R&D support will facilitate the development of decentralized clinical trial technology, providing participants with options for virtual visits and mobile reporting. This strategic investment aims to improve clinical trial efficiency and participation, reduce costs, and ensure real-time data access. The funding highlights ICON's commitment to advancing clinical research and delivering better patient outcomes globally.
ICON plc (NASDAQ: ICLR) announced that CFO Brendan Brennan will present at two upcoming healthcare conferences. He will speak at the Wells Fargo 16th Annual Healthcare Conference on September 9, 2021, at 8:00 AM ET, and at the Baird Global Healthcare Conference on September 15, 2021, at 8:30 AM ET.
Investors can find updates on these events and links to live webcasts on the Investor section of ICON's website. As of June 30, 2021, ICON employed approximately 16,480 employees across 89 locations worldwide.
ICON plc (NASDAQ: ICLR) reported a strong Q2 2021, showcasing a record net business win of $1,106 million and a remarkable revenue increase of 40.5% year-over-year to $871 million. Adjusted EPS surged by 76.8% to $2.12. The acquisition of PRA is poised to enhance growth and shareholder value, with updated revenue guidance for 2021 between $5,300 million and $5,500 million. Cash generated from operations was $128.4 million, while net cash reached $707.2 million. Overall, the results highlight a robust financial position and positive outlook for the company.
ICON plc (NASDAQ: ICLR) successfully held its Annual General Meeting (AGM) on July 20, 2021, where all recommended resolutions were passed by shareholders. Key resolutions included re-election of directors, approval of financial reports, and authorizations for share allotment and market purchases. Approximately 45.4 million votes were cast. Notable outcomes were re-elections of Ciaran Murray, Joan Garahy, and Eugene McCague, alongside approvals for the fixing of auditors’ remuneration and disapplication of pre-emption rights. The company continues to emphasize growth and innovation in clinical research.
ICON plc (NASDAQ: ICLR) has completed its acquisition of PRA Health Sciences, forming a combined entity with 38,000 employees across 47 countries. The merger aims to create a leading healthcare intelligence and clinical research organization, enhancing clinical trials and accelerating drug development through advanced technology and diverse patient access. PRA shareholders received $80 in cash and 0.4125 shares of ICON stock. This strategic move positions ICON to improve biopharma customers' success in bringing essential medicines and devices to market.
FAQ
What is the current stock price of ICON PLC (ICLR)?
What is the market cap of ICON PLC (ICLR)?
